In contrast to findings with behavioral 20,21,22 and other pharmacological interventions 10,12,13 , the similar mean weight loss achieved with semaglutide 2.4 mg in STEP 5 at weeks 52 and 104 (15.6% and 15.2%, respectively) suggests that, on average, there is minimal weight regain over 104 weeks when once-weekly semaglutide therapy is continued
This secondary purpose allows it to provide the same basic effects as semaglutide but with a dual action that is potentially more beneficial
Sermorelin Tesamorelin is an FDA-approved GHRH used specifically to reduce abdominal fat
GLP-1 receptor agonists represent a hard-earned pharmacological breakthrough, offering potent glucose control and unprecedented weight loss
Percent change from baseline in body weight, change from baseline in waist circumference and waist-to-height ratio (WHtR), and the proportion of participants achieving body weight reduction thresholds ( 10%, 15%, 20%, 25%, and 30%) were also assessed at Week 72
Health experts suggest that tirzepatide may be a more holistic choice when it comes to managing weight, as this medication presents advantages that go beyond regulating blood sugar levels